阳性患者样本中ROS1融合检测方法的比较
结果显示没有一种方法敏感性达100%:FISH在2/20例阴性,DNA-based NGS在4/18例阴性,RNA-based NGS在3/19例阴性。研究者指出各方法均有导致假阴性的特性,且基因组断点不能可靠预测转录本水平断点。
要点
- 三种常用ROS1检测方法均存在假阴性,无100%敏感性。
- FISH、DNA-based NGS和RNA-based NGS在阳性样本中分别有2/20、4/18和3/19例阴性。
- 基因组断点不能可靠预测转录本水平断点,可能因可变剪接。
核心结论
- 临床ROS1重排/融合检测复杂,所有方法均有固有局限,用户须知晓以正确解读结果。
主要发现
- FISH在20例可评估样本中2例阴性。
- DNA-based NGS在18例可评估样本中4例阴性。
- RNA-based NGS在19例可评估样本中3例阴性。
- 三种方法均鉴定出可能导致假阴性的检测特征。
- 基因组断点不能可靠预测转录本水平断点,可能因可变剪接。
临床怎么用
- 临床检测ROS1融合时应了解所用方法的局限性,对阴性结果结合临床和其他方法综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: ROS1 gene fusions are a well-characterized class of oncogenic driver found in approximately 1% to 2% of NSCLC patients. ROS1-directed therapy in these patients is more efficacious and is associated with fewer side effects compared to chemotherapy and is thus now considered standard-of-care for patients with advanced disease. Consequently, accurate detection of ROS1 rearrangements/fusions in clinical tumor samples is vital. In this study, we compared the performance of three common molecular testing approaches on a cohort of ROS1 rearrangement/fusion-positive patient samples. METHODS: Twenty-three ROS1 rearrangement/fusion-positive clinical samples were assessed by at least two of the following molecular testing methodologies: break-apart fluorescence in situ hybridization, DNA-based hybrid capture library preparation followed by next-generation sequencing (NGS), and RNA-based anchored multiplex polymerase chain reaction library preparation followed by NGS. RESULTS: None of the testing methodologies demonstrated 100% sensitivity in detection of ROS1 rearrangements/fusions. Fluorescence in situ hybridization results were negative in 2 of 20 tested samples, the DNA-based NGS assay was negative in 4 of 18 tested samples, and the RNA-based NGS assay was negative in 3 of 19 tested samples. For all three testing approaches, we identified assay characteristics that likely contributed to false-negative results. Additionally, we report that genomic breakpoints are an unreliable predictor of breakpoints at the transcript level, likely due to alternative splicing. CONCLUSIONS: ROS1 rearrangement/fusion detection in the clinical setting is complex and all methodologies have inherent limitations of which users must be aware to correctly interpret results.
引用
- Davies KD, Le AT, Sheren J, et al. Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol. 2018. PMID: 29935306. doi:10.1016/j.jtho.2018.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。